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Cochrane Library, the Springer Database and four Chinese Biomedical
Databases through October 2014. We included only randomized con-
trolled trials (RCTs) using oral Chinese herbal medicine as a treatment
for adults with knee OA. To determine the effect of oral Chinese herbal
medicine on clinical symptoms we extracted the Visual Analogue Scale
(VAS, range 0-10) and the Western Ontario and McMaster Universities
Arthritis Index pain scores (WOMAC pain, range 0-20), where lower
score indicates a better outcome. Study quality was assessed with Jadad
criteria regarding randomization blinding and dropout rates for each
study. VAS pain and WOMAC pain outcomes were synthesized sepa-
rately using random-effects meta-analyses.
Results: We identiﬁed 1530 potentially relevant studies. Twenty-four
studies totaling 2422 participants (64% female) met the eligibility cri-
teria. Table 1 summarizes the RCTs of oral Chinese herbal medicine on
pain measures (VAS and WOMAC scale). Subjects’ mean age was 58
years and mean symptom duration was 5.3 years. All studies were
conducted in China between 2004 and 2014; one study was published
in English. For the treatment groups, an average of 9 Chinese herbs were
prescribed for pain treatment based on the syndrome differentiation,
via infusion of the herbs with hot water and oral administration for one
to three times a day. Mean treatment duration was 6.9 weeks (range 2-
24 weeks) for 1-2 courses of treatment. No other treatments besides
herbal medicine were prescribed. Control group treatments included
oral administration of Glucosamine, non-steroidal anti-inﬂammatory
drugs (NSAIDs), Alendronate sodium, or intra-articular hyaluronate
injection. Overall quality of trials was modest (mean Jadad score¼2.9).
Nineteen studies showed signiﬁcantly improved VAS pain scores
compared to control groups (Mean Difference [MD] ¼ 0.57; 95% con-
ﬁdence interval [CI], 0.17 to 0.98; p<0.01). Six studies showed sig-
niﬁcantly improved WOMAC pain scores compared to control (MD ¼
2.23; 95% CI, 0.56 to 3.91; p<0.01).
Conclusions: These studies suggest that oral Chinese herbal medicine
has potential beneﬁts in pain relief for patients with knee OA compared
to standard westernmedications. Further rigorously designed andwell-
controlled RCTs are warranted.Table 1
Twenty-four RCTs of Chinese Herbs Medicine on Knee Osteoarthritis
Author (Year) N Age Chinese Herbs Controls
Cao, 2004 60 63 3 herbs, 0.35g3#, 3x/day Glucosamine, 0.375
Ji, 2008 50 59 9 herbs, 3x/day Glucosamine, 250m
Qi, 2009 337 55 14 Herbs: 10-30g each, 2x/day Glucosamine, 2#, 3
Li, 2012 89 61 6 herbs, 6g total, 2x/day Glucosamine, 250m
Tao, 2012 120 60 8 herbs: 10-30g each, 2x/day Glucosamine, 480m
Zhu, 2013 86 65 1 herb, 60mg total, 2x/day Glucosamine, 240m
Tang, 2014 63 55 7 herbs: 5-30g each, 2x/day Glucosamine, 750m
Ma, 2009 118 52 9 herbs: 10-15g each, 3x/day Celecoxib, 200mg,
Zhang, 2009 60 53 14 herbs: 6-30g each, 2x/day Celecoxib, 100mg,
Fan, 2012 152 50 14 herbs: 3-15g each, 2x/day Celecoxib, 200mg,
Liu, 2012 57 61 4 herbs, 1.68g total, 3x/day Celecoxib, 200mg,
Gao, 2012 96 58 9 herbs: 10-50g each, 2x/day Celecoxib, 200mg,
Diacerein, 50mg, 2
Zhang, 2013 60 55 15 herbs: 0.6-30g each, 1x/day Celecoxib, 200mg,
Fu, 2014 86 61 11 herbs: 6-15g each, 2x/day Celecoxib, 200mg,
Glucosamine, 628m
Deng, 2008 100 59 4 Herbs: 6-12g each, 1x/day Diclofenac sodium,
Kan, 2011 114 53 17 Herbs, 2.0g total, 3x/day Diclofenac sodium,
Liu, 2011 80 58 11 herbs, 1.2g total, 3x/day Diclofenac sodium,
Sun, 2012 60 57 1 herb, 1.2g total, 3x/day Diclofenac sodium,
Deng, 2009 160 60 5Herbs: 6-12 geach, 1x/day Meloxicam, 75mg,
Han, 2014 60 57 20 herbs: 5-45g each, 2x/day Meloxicam, 7.5mg,
Xie, 2010 176 60 10 Herbs, 0.5-3.0g each, 2x/day Ibuprofen, 0.6g, 2x
Lin, 2013 120 57 9 herbs: 6-30g each, 2x/day Alendronate Sodium
Lin, 2014 78 55 1 herb, 3#, 3x/day Alendronate Sodium
Yang, 2012 40 62 4 herbs: 10-20g each, 2x/day Hyaluronate injecti
N¼ number of patients included; Age reported in years as a mean; VAS Score: 0-10, lowe
Main ingredients for pain relief: White Paeony Root, Clematis Root, Doubleteeth Pubesc
Divaricate Saposhnikovia Root, Szechuan Lovage Rhizome, Manchurian Wildginger; Commo587
PREDICTING RESPONSE TO OSTEOARTHRITIS TREATMENT: PATIENT
PHENOTYPE BASED ON PATIENT REPORTED OUTCOME MEASURES
AND QUANTITATIVE SENSORY TESTING IN A CLINICAL TRIAL
K. Phillips. Univ. of Michigan, Ann Arbor, MI, USA
Purpose: Recent studies have suggested that a subset of individuals
with chronic pain state may have central sensitization. This subset of
patients with centralized pain can theoretically be identiﬁed via self
-report measures, quantitative sensory testing, and/or neuroimaging.
This study examined whether phenotyping patients by self-report or
QST measures of pain centralization predicted a differential response
amongst OA patients to a centrally-acting (duloxetine) vs. peripherally-
acting (topical diclofenac) analgesic, or both together.
Methods: Fifty patients were enrolled in a double-blind crossover trial
where each was treated with duloxetine or four times daily 1.5% topical
diclofenac solution. Outcomes included WOMAC pain subscale, Pain-
DETECT, Pain Quality Assessment Scale (PQAS), PROMIS physical func-
tion Short Form, PROMIS fatigue Short Form, Pressure Pain Threshold,
and Conditioned PainModulation. Therewere a total of three treatment
periods, each lasting for eight weeks followed by a for week washout
period. Patient were randomized as to the order in which they received
either duloxetine, topical diclofenac, or the combination. The primary
endpoint was a change in the WOMAC pain subscale.
Results: Treatment with duloxetine resulted in a signiﬁcant decrease in
WOMAC pain subscale whereas there was no signiﬁcant improvement
in the group means in the 1.5% diclofenac treatment period. QST
assessment or baseline pressure pain threshold predicted the response
to duloxetine, but there was no association between QST measures of
conditioned painmodulation and response to duloxetine. An increase in
the PainDETECT score was associated with an increase in pain as
measured by the WOMAC pain subscale by an average of 0.22 per unit
increase in pain DETECT score (SE 0.059, p¼0.0005). There were no
differences in adverse events or rescue medication usage between the
arms. There was no evidence of carry-over effect on PainDETECT scores,
p¼0.93.
Conclusions: Pain control was most favorable for duloxetine alone or in
combination with topical diclofenac. Baseline PainDETECT, PQAS Inten-
sity, and Pressure Pain Threshold predicted response to duloxetine.Duration (wks) Results (Treatment vs. Control) P value
g2#, 3x/day 4 VAS: 1.8 vs. 2.0 >0.05
WOMAC: 11 vs. 14 >0.05
g, 3x/day 6 VAS: 2.6 vs. 3.4 <0.05
x/day 4 VAS: 1.22 vs. 2.46 <0.05
g, 2x/day 8 VAS: 4.22 vs. 7.40 <0.05
g, 2x/day 8 VAS: 3.09 vs. 3.16 >0.05
g, 2x/day 12 WOMAC: 3.6 vs. 4.5 <0.05
g, 3x/day 4 WOMAC: 6.31 vs. 9.33 <0.05
1x/day 12 VAS: 2.41 vs. 3.18 <0.05
2x/day 24 WOMAC: 6.03 vs. 7.14 <0.01
1x/day 8 VAS: 2.8 vs. 2.7 >0.05
1x/day 6 VAS: 1.34 vs. 1.12 >0.05
1x/day 4 VAS: 1.94 vs. 1.56 <0.05
x/day
2x/day 4 VAS: 2.25 vs. 5.45 <0.05
1x/day 8 WOMAC: 3.19 vs. 8.51 <0.05
g, 3x/day
75mg, 1x/day 2 VAS: 1.55 vs. 1.50 >0.05
25mg, 1x/day 8 VAS: 1.93 vs. 1.93 >0.05
75mg, 2x/day 4 VAS: 3.89 vs. 4.79 <0.05
75mg, 1x/day 4 WOMAC: 13.8vs. 14.0 >0.05
1x/day 2 VAS: 2.86 vs. 3.29 >0.05
1x/day 4 VAS: 2.43 vs. 3.48 <0.01
/day 4 VAS: 2.6 vs. 4.2 <0.01
, 70mg, 1x/wk 8 VAS: 3.51 vs. 3.43 >0.05
, 70mg, 1x/wk 12 VAS: 2.42 vs. 4.17 <0.05
on, 2ml, 1x/wk 5 VAS: 3.1 vs. 3.0 >0.05
r score ¼ better outcome; WOMAC Pain Score: 0-20, lower score ¼ better outcome;
ent Angilica Root, Common Floweringquince Fruit, Slenderstyle Acanthopanax Bark,
n Monkshood Mother Root, Cassia Twig, Kusnezoff Monkshood Root.
